DE1132556B - Process for the preparation of derivatives of 5- (ª † -piperazino-propyl) -dibenzo [b, f] azepine - Google Patents
Process for the preparation of derivatives of 5- (ª † -piperazino-propyl) -dibenzo [b, f] azepineInfo
- Publication number
- DE1132556B DE1132556B DEG27713A DEG0027713A DE1132556B DE 1132556 B DE1132556 B DE 1132556B DE G27713 A DEG27713 A DE G27713A DE G0027713 A DEG0027713 A DE G0027713A DE 1132556 B DE1132556 B DE 1132556B
- Authority
- DE
- Germany
- Prior art keywords
- dibenzo
- azepine
- formula
- propyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- KDUIIIUHZIHOHE-UHFFFAOYSA-N 11-(3-piperazin-1-ylpropyl)benzo[b][1]benzazepine Chemical class C12=CC=CC=C2C=CC2=CC=CC=C2N1CCCN1CCNCC1 KDUIIIUHZIHOHE-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- CXHRHQJOTCKDBC-UHFFFAOYSA-N 3-benzo[b][1]benzazepin-11-ylpropan-1-ol Chemical compound OCCCN1C(C=CC=C2)=C2C=CC2=C1C=CC=C2 CXHRHQJOTCKDBC-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 antiallergic Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- YULFFYZCWUUTNC-YWPNNVDBSA-N (1r)-1-[(4r,4ar,8as)-2,6-bis(4-chlorophenyl)-4-methyl-8,8a-dihydro-4ah-[1,3]dioxino[5,4-d][1,3]dioxin-4-yl]ethane-1,2-diol Chemical compound C([C@@H]1OC(O[C@]([C@@H]1O1)(C)[C@H](O)CO)C=2C=CC(Cl)=CC=2)OC1C1=CC=C(Cl)C=C1 YULFFYZCWUUTNC-YWPNNVDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ZPJZSEHCMJYUPI-UHFFFAOYSA-N methyl piperazine-1-carboxylate Chemical compound COC(=O)N1CCNCC1 ZPJZSEHCMJYUPI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical class OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
DEUTSCHESGERMAN
PATENTAMTPATENT OFFICE
G 27713 IVd/12ρG 27713 IVd / 12ρ
ANMELDETAG: 12. AU G U S T 1959REGISTRATION DATE: AUG U S T 12, 1959
BEKANNTMACHUNG DER ANMELDUNG UNDAUSGABEDER AUSLEGESCHRIFT:NOTICE THE REGISTRATION ANDOUTPUTE EDITORIAL:
5. JULI 1962JULY 5, 1962
Die Erfindung betrifft ein Verfahren zur Herstellung von Derivaten des 5-(y-Piperazinopropyl)-dibenzo-[b,f]azepins der allgemeinen FormelThe invention relates to a process for the preparation of derivatives of 5- (γ-piperazinopropyl) -dibenzo- [b, f] azepine the general formula
(CHJ1-N,(CHJ 1 -N,
,N —CH^-CH2-OR, N -CH ^ -CH 2 -OR
worin R ein Wasserstoffatom oder eine niedrigmolekulare gesättigte aliphatische Acylgruppe bedeutet, und von deren Salzen. Diese Verbindungen besitzen wertvolle pharmakologische Eigenschaften, insbesondere sedative, antikonvulsive, antiallergische, antiemetische, antiophlogistische und antipyretische Wirksamkeit, und sind als Psychotherapeutica, insbesondere zur Behandlung von Gemütsdepressionen, verwendbar.where R is a hydrogen atom or a low molecular weight saturated aliphatic acyl group, and their salts. These compounds have valuable pharmacological properties, especially sedative, anticonvulsant, antiallergic, antiemetic, antiophlogistic and antipyretic Efficacy, and are used as psychotherapeutics, especially for the treatment of mood depression, usable.
Zur Erzielung derselben histaminantagonistischeii Wirkung am isolierten Meerschweinchendarm ist von dem neuen 5-{y-(4'-Hydroxyäthylpiperazino)-propyl}-dibenzo[b,f]azepin [R = H in obiger Formel I] nur ein Drittel und zur Erzielung derselben histaminentgiftenden Wirkung am lebenden Meerschweinchen nur ein Sechzehntel der vom bekannten 5-{y-(4'-Methylpiperazino) - propyl} - dibenzo [b, f ] azepin benötigten Menge erforderlich. Die Antihistaminwirksamkeit der neuen Verbindung ist also viel ausgeprägter.To achieve the same histamine-antagonistic effect on the isolated guinea pig intestine, from the new 5- {y- (4'-Hydroxyäthylpiperazino) -propyl} -dibenzo [b, f] azepine [R = H in above formula I] only a third and to achieve the same histamine detoxifying Effect on living guinea pigs is only one sixteenth that of the well-known 5- {y- (4'-methylpiperazino) - propyl} - dibenzo [b, f] azepine required amount. The antihistamine effectiveness the new connection is therefore much more pronounced.
Zur Herstellung der Verbindungen der allgemeinen Formel I setzt man in an sich bekannter Weise entwederTo prepare the compounds of general formula I, either in a manner known per se
a) einen reaktionsfähigen Ester des 5-(y-Hydroxypropyl)-dibenzo[b,f)azepins der Formela) a reactive ester of 5- (γ-hydroxypropyl) -dibenzo [b, f) azepine the formula
' N v ' N v
(CH2)3-OH II(CH 2 ) 3 -OH II
mit N-(/3-Hydroxyäthyl)-piperazin der Formelwith N - (/ 3-hydroxyethyl) piperazine of the formula
HNn N-CH2-CH2-OH IIIHN n N-CH 2 -CH 2 -OH III
um, oder man bringtaround, or one brings
Verfahren zur HerstellungMethod of manufacture
von Derivaten des 5-(y-Piperazino-propyl)-of derivatives of 5- (y-piperazino-propyl) -
dibenzo [b,f ] azepinsdibenzo [b, f] azepins
Anmelder: J. R. Geigy A.-G., Basel (Schweiz)Applicant: J. R. Geigy A.-G., Basel (Switzerland)
Vertreter: Dr. F. Zumstein,Representative: Dr. F. Zumstein,
Dipl.-Chem. Dr. rer. nat. E. AssmannDipl.-Chem. Dr. rer. nat. E. Assmann
und Dipl.-Chem. Dr. R. Koenigsberger,and Dipl.-Chem. Dr. R. Koenigsberger,
Patentanwälte, München 2, Bräuhausstr. 4Patent Attorneys, Munich 2, Bräuhausstr. 4th
Beanspruchte Priorität: Schweiz vom 13. August 1958 (Nr. 62 880)Claimed priority: Switzerland of August 13, 1958 (No. 62 880)
Dr. Walter Schindler, Riehen (Schweiz), ist als Erfinder genannt wordenDr. Walter Schindler, Riehen (Switzerland), has been named as the inventor
b) 5-(y-Piperazinopropyl)-dibenzo[b,f)]azepin der Formelb) 5- (γ-piperazinopropyl) -dibenzo [b, f)] azepine der formula
(CH2J8-N,(CH 2 J 8 -N,
NHNH
mit einem reaktionsfähigen Monoester des Äthylenglykols zur Reaktion und verestert gegebenenfalls anschließend das erhaltene 5-{y-(4'-Hydroxyäthylpiperazino)-propyl}-dibenzo[b,f]azepin mit dem Anhydrid einer niedrigmolekularen gesättigten aliphatischen Carbonsäure.with a reactive monoester of ethylene glycol for reaction and then optionally esterifies the 5- {y- (4'-Hydroxyäthylpiperazino) -propyl} -dibenzo [b, f] azepine obtained with the anhydride of a low molecular weight saturated aliphatic carboxylic acid.
Geeignete reaktionsfähige Ester des 5-(y-Hydroxypropyl)-dibenzo(b,f)azepins der Formel II sind insbesondere dessen Halogenwasserstoffsäure- und Arylsulfonsäureester. Vorteilhaft ist die Durchführung der Umsetzung in Gegenwart von 1 Mol eines Alkalijodids in einem inerten organischen Lösungsmittel und Erhitzen des Reaktionsgemischs zum Sieden unter Rückfluß. Als Beispiele von geeigneten Ausgangsstoffen, für deren Herstellung kein Schutz beansprucht wird, seinen das 5-(y-Brompropyl)-, 5-(y-ChIorpropyl)- und 5-(y-p-Toluolsulfonyl-oxypropyl)-diben-Suitable reactive esters of 5- (γ-hydroxypropyl) -dibenzo (b, f) azepine of the formula II are, in particular, its hydrohalic acid and aryl sulfonic acid esters. It is advantageous to carry out the reaction in the presence of 1 mol of an alkali iodide in an inert organic solvent and heating the reaction mixture to the boil Reflux. As examples of suitable starting materials for the production of which no protection is claimed its the 5- (y-bromopropyl) -, 5- (y-chloropropyl) - and 5- (y-p-toluenesulfonyl-oxypropyl) -diben-
209 618/334209 618/334
zo[b,f]azepin genannt. Solche Verbindungen sind ihrerseits beispielsweise durch Umsetzung von Dibenzo [b,f]azepin mit reaktionsfähigen Diestern des Propan-1,3-diols, insbesondere solchen mit zwei verschiedenen Säurekomponenten, z. B. «-Brom-y-chlorpropan und Arylsulfonsäureestern von y-Chlor oder y-Brompropanol, erhältlich.zo [b, f] called azepine. Such compounds are in turn, for example, by reacting dibenzo [b, f] azepine with reactive diesters of Propane-1,3-diols, especially those with two different ones Acid components, e.g. B. «-Bromo-y-chloropropane and aryl sulfonic acid esters of γ-chlorine or γ-bromopropanol are available.
Das als Ausgangsstoff für die Verfahrensweise b) dienende 5-(y-Piperazinopropyi)-dibenzo[b,f ]azepin der Formel IV, für dessen Herstellung kein Schutz be- ίο ansprucht wird, ist z. B. durch Umsetzung der weiter oben genannten reaktionsfähigen Ester des 5-(y-Hydroxypropyl)-dibenzo[b,f]azepins mit leicht spaltbaren N-Acyl-piperazinen wie N-Formyl-, N-Acetyl- oder N-Carbomethoxy-piperazin und anschließende hydrolytische Abspaltung des Acylrestes zugänglich.The 5- (y-piperazinopropyi) -dibenzo [b, f] azepine serving as starting material for procedure b) Formula IV, for the production of which no protection is claimed, is z. B. by implementing the next Above-mentioned reactive ester of 5- (γ-hydroxypropyl) -dibenzo [b, f] azepine with easily cleavable N-acyl-piperazines such as N-formyl, N-acetyl or N-carbomethoxy-piperazine and subsequent hydrolytic cleavage of the acyl radical accessible.
Mit anorganischen oder organischen Säuren, wie Salzsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Methansulfonsäure, Äthansulfonsäure, Äthandisulfonsäure, Essigsäure, Bernsteinsäure, Fumarsäure, Maleinsäure, Äpfelsäure, Weinsäure, Citronensäure, Benzoesäure und Phthalsäure, bilden die tertiären Basen der allgemeinen Formel I ein- und zweisäurige Salze, welche zum Teil wasserlöslich sind.With inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, Methanesulphonic acid, ethanesulphonic acid, ethane disulphonic acid, acetic acid, succinic acid, fumaric acid, Maleic acid, malic acid, tartaric acid, citric acid, benzoic acid and phthalic acid, make up the tertiary bases of the general formula I mono- and di-acid salts, some of which are water-soluble.
Die nachfolgenden Beispiele sollen die Herstellung der neuen Verbindungen näher erläutern. Teile bedeuten darin Gewichtsteile, diese verhalten sich zu Volumteilen wie Gramm zu Kubikzentimeter. Die Temperaturen sind in Celsiusgraden angegeben.The following examples are intended to explain the preparation of the new compounds in more detail. Parts mean therein parts by weight, these are related to parts by volume as grams to cubic centimeters. the Temperatures are given in degrees Celsius.
3030th
19 Teile 5-(p-Chlorpropyl)-dibenzo[b,f]azepin werden in 130 Volumteilen Butanon gelöst und die Lösung nach Zusatz von 10 Teilen Natriumjodid und 19 Teilen N-(jS-Hydroxyäthyl)-piperazin 16 Stunden unter Kochen am Rückfluß gerührt. Hierauf destilliert man das Lösungsmittel ab, gibt Wasser zu und äthert das Ganze gründlich aus. Der ätherischen Lösung werden nach gründlichem Waschen mit Wasser die basischen Anteile durch dreimaliges Ausziehen mit verdünnter Salzsäure entzogen. Die sauren Auszüge werden alkalisch gestellt und die ausgeschiedene Base wieder in Äther aufgenommen. Nach dem Trocknen und Eindampfen der ätherischen Lösung hinterbleibt das 5-{y-(4'-Hydroxyäthylpiperazina)-propyl}-dibenzo-[b,f]azepin vom Schmelzpunkt 100°; Ausbeute: 88 %·19 parts of 5- (p-chloropropyl) -dibenzo [b, f] azepine become dissolved in 130 parts by volume of butanone and the solution after adding 10 parts of sodium iodide and 19 parts of N- (iS-hydroxyethyl) piperazine were stirred under reflux for 16 hours. Then distilled the solvent is removed, water is added and the whole thing is thoroughly etherified. The essential solution After thorough washing with water, the basic components are removed by pulling them out three times removed from dilute hydrochloric acid. The acidic extracts are made alkaline and the base which has separated out reabsorbed into ether. After drying and evaporation the essential solution remains 5- {y- (4'-Hydroxyäthylpiperazina) -propyl} -dibenzo- [b, f] azepine with a melting point of 100 °; Yield: 88%
Das mit alkoholischer Salzsäure bereitete Dihydrochlorid schmilzt bei 228 bis 230°.The dihydrochloride prepared with alcoholic hydrochloric acid melts at 228 to 230 °.
1 Teil des 5-{y-(4'-Hydroxyäthylpiperazino)-propyl}-dibenzo [b,f]azepins wird mit 5 Teilen Essigsäureanhydrid. 4 Stunden unter Rückfluß gekocht. Das überschüssige Acetanhydrid wird im Vakuum abgedampft, der Rückstand in kaltem Wasser gelöst, die Lösung filtriert und mit Natriumcarbonatlösung alkalisch gestellt. Der Niederschlag wird in Äther aufgenommen, die Ätherlösung mit Wasser gewaschen, über Natriumsulfat getrocknet und das Lösungsmittel abdestilliert. Der Rückstand wird in Petroläther gelöst, die Lösung filtriert und das Filtrat eingedampft. Das 5-{y-(4'-j5-Acetoxyäthylpiperazino)-propyl}-dibenzo[b,f]azepin wird als gelbes Öl erhalten; Ausbeute: 80%.1 part of the 5- {y- (4'-Hydroxyäthylpiperazino) -propyl} -dibenzo [b, f] azepins is mixed with 5 parts of acetic anhydride. Boiled under reflux for 4 hours. That Excess acetic anhydride is evaporated off in vacuo, the residue dissolved in cold water, the Solution filtered and made alkaline with sodium carbonate solution. The precipitate is in ether added, the ethereal solution washed with water, dried over sodium sulfate and the Solvent distilled off. The residue is dissolved in petroleum ether, the solution filtered and the filtrate evaporated. 5- {y- (4'-j5-acetoxyethylpiperazino) propyl} -dibenzo [b, f] azepine is obtained as a yellow oil; Yield: 80%.
1 Teil dieses Öles wird in wenig Aceton gelöst, worauf die berechnete Menge absolute alkoholische Salzsäure zugegeben wird. Das Dihydrochlorid kristallisiert nach einiger Zeit aus und schmilzt, aus Alkohol umkristallisiert, bei 209 bis 212°.1 part of this oil is dissolved in a little acetone, whereupon the calculated amount of absolute alcoholic hydrochloric acid is admitted. The dihydrochloride crystallizes out after some time and melts from alcohol recrystallized, at 209 to 212 °.
Zur Herstellung des als Ausgangsstoff benötigten 5-(p-Chlorpropyl)-dibenzo(b,f]azepins werden 19 Teile Dibenzo [b,f]azepin und 20 Teile l-Chlor-3-brompropan in 800 Volumteilen absolutem Benzol gelöst und zu der Lösung bei 50° unter starkem Rühren innerhalb 1I2 Stunde 4,4 Teile Natriumamid in Toluol zugetropft. Nach dem Zutropfen rührt man noch 3 Stunden bei 50 bis 60° und kocht anschließend 3 Stunden unter Rückfluß. Nach dem Abkühlen wird das Reaktionsgemisch mit Wasser versetzt und die Benzolschicht abgetrennt, mit Wasser gewaschen, getrocknet und eingedampft. Der ölige Rückstand wird in 400 Volumteilen Petroläther aufgenommen, noch vorhandenes ungelöstes Dibenzo [b,f]azepin wird abfiltriert und das Filtrat eingedampft, wobei das 5 - (y - Chlorpropyl) - dibenzo [b,f ] azepin zurückbleibt, welches nach Umkristallisation aus absolutem Äther bei 67° schmilzt; Ausbeute: 63%.To prepare the 5- (p-chloropropyl) -dibenzo (b, f] azepine required as starting material, 19 parts of dibenzo [b, f] azepine and 20 parts of l-chloro-3-bromopropane are dissolved in 800 parts by volume of absolute benzene and added to the 4.4 parts of sodium amide in toluene were added dropwise to the solution at 50 ° with vigorous stirring in the course of 1 1/2 hours added and the benzene layer separated off, washed with water, dried and evaporated. The oily residue is taken up in 400 parts by volume of petroleum ether, any undissolved dibenzo [b, f] azepine is filtered off and the filtrate is evaporated, whereby the 5 - (y - chloropropyl) - Dibenzo [b, f] azepine remains, which after recrystallization from absolute ether melts at 67 °; Yield: 63%.
16 Teile 5-(y-Piperazinopropyl)-dibenzo[b,f]azepin werden mit 7 Teilen Kaliumcarbonat und 6,35 Teilen /9-Bromäthanol in 15 Volumteilen Toluol 4 Stunden auf 120° erhitzt. Nach Abkühlen der Reaktionsmasse wird diese mit 50 Volumteilen Chloroform und 30 Volumteilen Wasser behandelt. Man dekantiert den wäßrigen Teil ab und extrahiert die Chloroformlösung mehrere Male mit verdünnter Salzsäure. Die vereinigten sauren Lösungen werden mit Kaliumcarbonat alkalisch gestellt, wobei die rohe Base ausfällt. Das ausgeschiedene Öl wird in Äther aufgenommen, die Lösung getrocknet und auf ein kleines Volumen eingeengt, worauf Kristallisation eintritt. Das so erhaltene 5-{y-(4'-Hydroxyäthylpiperazino)-propyl}-dibenzo[b,f]azepin schmilzt bei 100 bis 101°; Ausbeute 72%.16 parts of 5- (γ-piperazinopropyl) -dibenzo [b, f] azepine are mixed with 7 parts of potassium carbonate and 6.35 parts / 9-bromoethanol in 15 parts by volume of toluene for 4 hours heated to 120 °. After cooling the reaction mass, this is mixed with 50 parts by volume of chloroform and Treated 30 parts by volume of water. The aqueous part is decanted off and the chloroform solution is extracted several times with dilute hydrochloric acid. The combined acidic solutions are made with potassium carbonate made alkaline, whereupon the crude base precipitates. The excreted oil is absorbed into the ether Solution dried and concentrated to a small volume, whereupon crystallization occurs. The thus obtained 5- {y- (4'-Hydroxyäthylpiperazino) -propyl} -dibenzo [b, f] azepine melts at 100 to 101 °; yield 72%.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH6288058A CH368497A (en) | 1958-08-13 | 1958-08-13 | Process for the preparation of new derivatives of iminostilbene |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1132556B true DE1132556B (en) | 1962-07-05 |
Family
ID=4524598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DEG27713A Pending DE1132556B (en) | 1958-08-13 | 1959-08-12 | Process for the preparation of derivatives of 5- (ª † -piperazino-propyl) -dibenzo [b, f] azepine |
Country Status (8)
Country | Link |
---|---|
CH (1) | CH368497A (en) |
CY (1) | CY306A (en) |
DE (1) | DE1132556B (en) |
ES (1) | ES251414A1 (en) |
FR (1) | FR162M (en) |
GB (1) | GB921961A (en) |
MY (1) | MY6600067A (en) |
NL (1) | NL108935C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20030828A1 (en) * | 2003-04-18 | 2004-10-19 | Farchemia Srl | PROCEDURE FOR THE PREPARATION OF OPIPRAMOL. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE549299A (en) * | 1955-10-20 | |||
DE939630C (en) * | 1953-10-25 | 1956-03-01 | Basf Ag | Process for the preparation of heterocyclic compounds with a ring-shaped imino group substituted by basic groups |
-
0
- NL NL108935D patent/NL108935C/xx active
-
1958
- 1958-08-13 CH CH6288058A patent/CH368497A/en unknown
-
1959
- 1959-08-12 GB GB27521/59A patent/GB921961A/en not_active Expired
- 1959-08-12 DE DEG27713A patent/DE1132556B/en active Pending
- 1959-08-12 ES ES0251414A patent/ES251414A1/en not_active Expired
-
1960
- 1960-08-09 FR FR835430A patent/FR162M/en active Active
-
1965
- 1965-02-02 CY CY30665A patent/CY306A/en unknown
-
1966
- 1966-12-31 MY MY6600067A patent/MY6600067A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE939630C (en) * | 1953-10-25 | 1956-03-01 | Basf Ag | Process for the preparation of heterocyclic compounds with a ring-shaped imino group substituted by basic groups |
BE549299A (en) * | 1955-10-20 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
Also Published As
Publication number | Publication date |
---|---|
FR162M (en) | 1961-02-13 |
NL108935C (en) | |
CY306A (en) | 1965-02-02 |
CH368497A (en) | 1963-04-15 |
GB921961A (en) | 1963-03-27 |
ES251414A1 (en) | 1960-03-01 |
MY6600067A (en) | 1966-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2426149C3 (en) | 7-Fluoro-substituted phenothiazines, processes for their preparation and pharmaceutical compositions containing them | |
DE1132556B (en) | Process for the preparation of derivatives of 5- (ª † -piperazino-propyl) -dibenzo [b, f] azepine | |
DE1153745B (en) | Process for the preparation of 4-halo-3-sulfamoylbenzoic acid esters | |
DE1795176B2 (en) | N'-substituted 5-aminoacetyl-5,10-dihydro-1 lH-dibenzo square brackets on b, square brackets on square brackets on 1,4 square brackets on diazepin-11one and process for their preparation | |
DE1695812A1 (en) | New derivatives of c, f-dibenzo-1,2-thiazepine and processes for their preparation | |
DE2160911A1 (en) | Process for the preparation of aminoketones | |
AT217045B (en) | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5H-dibenzo [b, f] azepines and 5H-dibenzo [b, f] azepines | |
AT219613B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
DD149666A1 (en) | PROCESS FOR THE PREPARATION OF 6-AMINO AND 6-HYDROXY-1-ARYL-5-CYAN-2 (1H) -PYRIDINONE AND THIONES | |
DE1445858C3 (en) | 7-cyano-5-phenyl-1,2-dihydro-3H-1,4benzodiazepin-2-one derivatives | |
AT235293B (en) | Process for the preparation of new piperidine derivatives | |
CH505852A (en) | Benzoxazepinones anti-inflammatory analgesic | |
AT212327B (en) | Process for the preparation of new derivatives of iminodibenzyl | |
AT268321B (en) | Process for the preparation of new heterocyclic compounds and their salts | |
DE1133729B (en) | Process for the preparation of 5- {ª † - (4'-Hydroxyaethylpiperazino) -propyl} -dibenzo [b, f] azepine | |
AT239794B (en) | Process for the preparation of new benzoxazepine derivatives | |
AT219606B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
DE2065311C3 (en) | v- (4-Hydroxy-4-phenylpiperidino) -2-amino-4fluorobutyrophenones, processes for their preparation and pharmaceuticals containing these compounds | |
AT267514B (en) | Process for the preparation of new pyrrolidine derivatives and their salts | |
AT343119B (en) | PROCESS FOR THE PREPARATION OF NEW 10H-THIENO (3,2-C) (1) BENZAZEPINE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS | |
AT231425B (en) | Process for the preparation of new basic compounds and their salts | |
AT233014B (en) | Process for the preparation of new iminodibenzyl derivatives | |
DE1493567C3 (en) | Esters of alpha-alkylthyroxine derivatives and process for their preparation | |
AT217044B (en) | Process for the preparation of new monoalkylated or monohalogenated N-derivatives of 10,11-dihydro-5 H-dibenzo [b, f] azepines and 5 H-dibenzo [b, f] azepines | |
DE2114511C3 (en) | 2-Alkyl-6,7-benzomorphanes, process for their preparation and their further processing to give 2-Benzoalkyl-6,7-benzomorphanes |